Apogee Therapeutics, Inc.
A clinical-stage biotechnology company developing antibody medicines for inflammatory and immune diseases such as atopic dermatitis, asthma, and COPD. Founded in 2022 as the first spinout from the Waltham, Massachusetts biotech Paragon Therapeutics, it engineers antibodies with longer half-lives so patients may need injections only every few months instead of weekly. The company went public on the Nasdaq in 2023.
Granted 3.0K · Sold 160.0K
Granted 16.5K · Sold 48.4K
Sold 10.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Henderson Michael ThomasChief Executive Officer, Director · 16 transactions | -13.5% | 1.02M | 3.0K | — | 160.0K |
| Dambkowski CarlChief Medical Officer · 14 transactions | -15.1% | 179.2K | 16.5K | — | 48.4K |
| Henderson JaneChief Financial Officer · 11 transactions | -5.3% | 173.7K | — | — | 10.0K |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 6 months: -218.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.